WVE Wave Life Sciences, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1631574 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-72.6%
TTM EPS YoY-64.6%
Revenue 3-yr CAGR-6.0%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-320.9%
Net margin-296.9%
FCF margin-293.8%
EBITDA margin-316.1%
Returns
ROE-80.0%
ROA-56.2%
ROIC (approx.)-270.5%
Asset turnover0.19x
Leverage & solvency
Liabilities / assets20.9%
Debt / equity0.00x
Current ratio8.38x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.98x
Accruals ratio-0.9%
Payout ratio—
Capex / revenue1.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $42.73M | $108.30M | $113.31M | $3.65M | $40.96M |
| R&D expense | $182.78M | $159.68M | $130.01M | $115.86M | $121.88M |
| SG&A expense | $75.33M | $59.02M | $51.29M | $50.51M | $46.10M |
| Operating income | -$215.38M | -$110.40M | -$68.00M | -$162.72M | -$127.02M |
| Pretax income | -$204.38M | -$97.01M | -$58.19M | -$161.14M | -$122.45M |
| Income tax | $0 | $0 | -$677,000 | $681,000 | -$204,000 |
| Net income | -$204.38M | -$97.01M | -$57.51M | -$161.82M | -$122.25M |
| EBITDA | -$211.94M | -$106.51M | -$63.00M | -$156.15M | -$119.53M |
| EPS (basic) | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 |
| EPS (diluted) | -1.21 | -0.70 | -0.54 | -2.05 | -2.36 |
| Weighted avg. shares (diluted) | 168.65M | 138.28M | 106.10M | 78.86M | 51.83M |
| Balance sheet | |||||
| Cash & equivalents | $602.07M | $302.08M | $200.35M | $88.50M | $150.56M |
| Short-term investments | $0 | — | — | — | — |
| Receivables | $1.28M | $1.42M | $21.09M | — | — |
| Current assets | $614.81M | $320.39M | $235.37M | $98.54M | $162.56M |
| PP&E, net | $7.41M | $10.13M | $13.08M | $17.28M | $22.27M |
| Total assets | $638.50M | $352.21M | $274.95M | $146.39M | $207.01M |
| Current liabilities | $95.06M | $110.95M | $186.44M | $71.52M | $64.20M |
| Total liabilities | $112.27M | $134.82M | $227.44M | $183.60M | $166.63M |
| Shareholders' equity | $518.36M | $209.51M | $39.63M | -$45.09M | $32.50M |
| Shares outstanding | 0 | 153.04M | 119.16M | 86.92M | 59.84M |
| Cash flow statement | |||||
| Operating cash flow | -$187.49M | -$151.03M | -$19.43M | -$127.78M | -$88.99M |
| Capital expenditure | $718,000 | $938,000 | $1.11M | $1.36M | $560,000 |
| Free cash flow | -$188.21M | -$151.96M | -$20.55M | -$129.14M | -$89.55M |
| Investing cash flow | -$718,000 | -$938,000 | -$1.11M | -$1.25M | -$560,000 |
| Financing cash flow | $488.24M | $253.89M | $132.53M | $67.19M | $55.83M |
| Depreciation & amortization | $3.44M | $3.90M | $5.00M | $6.57M | $7.48M |
| Stock-based compensation | $24.97M | $13.14M | $9.79M | $17.19M | $16.41M |
Free plan shows the latest 5 periods; Pro shows all 13 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.